Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …

BCG immunotherapy is the gold-standard treatment for non-muscle-invasive bladder cancer
at high risk of recurrence or progression. Preclinical and clinical studies have revealed that a …

Abstract Bacillus Calmette–Guérin (BCG) has been used to treat non-muscle-invasive
bladder cancer for more than 30 years. It is one of the most successful biotherapies for …

It is nearly 40 years since Bacillus Calmette–Guérin (BCG) was first used as an
immunotherapy to treat superficial bladder cancer. Despite its limitations, to date it has not …

Accumulating evidence demonstrates that the oral pathobiont Fusobacterium nucleatum is
involved in the progression of an increasing number of tumors types. Thus far, the …

Natural killer (NK) cells play critical roles in host immunity against cancer. In response,
cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current …

Over 30 years' successful application of Bacillus Calmette Guerin (BCG) to the clinical
treatment of bladder cancer has proved it one of the most promising immunotherapies for …

Abstract Background Patients with Bacillus Calmette–Guérin (BCG)–unresponsive non–
muscle-invasive bladder cancer (NMIBC) have limited treatment options. The immune cell …

BACKGROUND: Intravesical chemotherapy and bacillus Calmette-Guérin (BCG) reduce the
recurrence rate in patients with stage Ta T1 urothelial bladder cancer; however, the benefit …

Current insights into the molecular specificities that regulate natural killer (NK)-cell function
suggest that it might be possible to design NK-cell-based immunotherapeutic strategies …